{
    "nctId": "NCT01337765",
    "briefTitle": "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients",
    "officialTitle": "A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "Incidence of Dose Limiting Toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* histologically/cytologically confirmed, advanced non resectable solid tumors\n* Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0\n\nExclusion Criteria:\n\n* Patients with primary CNS tumor or CNS tumor involvement\n* Diabetes mellitus - Unacceptable ocular/retinal conditions\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}